GreenJay Therapeutics

GreenJay Therapeutics is a preclinical-stage biotechnology company focused on the development of next-generation cytokine therapies for cancer immunotherapy. The company's core technology is based on the structural biology and protein engineering research of Dr. K. Christopher Garcia at Stanford University, which allows for the creation of tuned cytokines. These engineered proteins are designed to selectively target specific immune cell populations, thereby maximizing anti-tumor activity while minimizing the severe systemic toxicities typically associated with wild-type cytokine treatments. GreenJay is backed by 6 Dimensions Capital and operates within a network of companies dedicated to translating complex molecular insights into clinical-stage biologics.